Vascular Biogenics Stock Price

-0.025 (-1.18%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Vascular Biogenics Ltd VBLT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.025 -1.18% 2.095 10:48:26
Open Price Low Price High Price Close Price Prev Close
2.15 2.07 2.1699 2.12
Bid Price Ask Price Spread News
2.09 2.10 0.01 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
110 42,981 $ 2.10 $ 90,430 - 1.0122 - 3.17
Last Trade Time Type Quantity Stock Price Currency
10:48:26 100 $ 2.095 USD


Draw Mode:

Vascular Biogenics Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 126.30M 60.29M 45.61M $ 922.00k $ - -0.56 -4.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Vascular Biogenics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VBLT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.162.281.962.10393,512-0.065-3.01%
1 Month2.222.591.962.33375,069-0.125-5.63%
3 Months1.883.041.782.40548,9900.21511.44%
6 Months2.383.171.652.17825,010-0.285-11.97%
1 Year1.303.171.01221.98656,0120.79561.15%
3 Years1.863.170.601.75330,9120.23512.63%
5 Years3.949.050.602.65279,911-1.85-46.83%

Vascular Biogenics Description

Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.

Your Recent History
Vascular B..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.